Josep Tabernero is a distinguished expert in medical oncology currently serving as the Director of Vall d’Hebron Institute of Oncology (VHIO) and Head of the Medical Oncology Department at Vall d’Hebron University Hospital. His research centers on molecular targeted therapies, targeting specific oncoproteins and novel immunotherapies to advance and accelerate more effective personalized cancer medicines for patients displaying genetic lesions or pathway dysregulation. He has expertise in predictive markers of response to anti-cancer therapies and innovative preclinical models (patient-derived xenografts and organoids) for studying tumor development. Josep served as President of the European Society for Medical Oncology (ESMO) from 2018-2019 and has been an active member of its Executive Board and multiple educational and scientific committees across ESMO, AACR, and ASCO. He actively contributes to various scientific committees and prestigious journals, driving progress in oncology globally. He is the Chair of Cancer Core Europe and a member of the Board of Directors of the Organisation of European Cancer Institutes (OECI).